Pennant Group Framtida tillväxt
Future kriterier kontrolleras 3/6
Pennant Group förväntas öka vinsten och intäkterna med 28.2% och 7.7% per år respektive medan EPS förväntas växa med 25.2% per år.
Viktig information
28.2%
Tillväxttakt i vinsten
25.22%
Tillväxttakt för EPS
| Healthcare vinsttillväxt | 17.4% |
| Intäkternas tillväxttakt | 7.7% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 07 Aug 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.
Uppdatering av berättelse • Jul 16
PNTG: Sector Tailwinds And Tech Investments Are Expected To Support Steady Upside
The analyst price target for Pennant Group has increased from $40.83 to $43.50. Analysts attribute this change to supportive sector trends in healthcare services, anticipated demand for care, and ongoing investments in growth and technology, which are key drivers behind their updated assumptions.Uppdatering av berättelse • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.Analysartikel • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
Uppdatering av berättelse • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.Uppdatering av berättelse • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Uppdatering av berättelse • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.Uppdatering av berättelse • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Uppdatering av berättelse • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Uppdatering av berättelse • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Uppdatering av berättelse • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Uppdatering av berättelse • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Uppdatering av berättelse • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Analysartikel • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Uppdatering av berättelse • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Uppdatering av berättelse • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Uppdatering av berättelse • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Analysartikel • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Analysartikel • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Analysartikel • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Analysartikel • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Analysartikel • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analysartikel • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Analysartikel • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Analysartikel • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Analysartikel • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Ny berättelse • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Analysartikel • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Analysartikel • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 1,329 | 68 | 75 | N/A | 3 |
| 12/31/2027 | 1,272 | 56 | 57 | 71 | 7 |
| 12/31/2026 | 1,178 | 42 | 41 | 58 | 7 |
| 6/30/2026 | 1,102 | 32 | 26 | 53 | N/A |
| 3/31/2026 | 1,023 | 30 | 41 | 66 | N/A |
| 12/31/2025 | 948 | 30 | 26 | 48 | N/A |
| 9/30/2025 | 847 | 27 | 28 | 48 | N/A |
| 6/30/2025 | 799 | 27 | 24 | 42 | N/A |
| 3/31/2025 | 748 | 25 | 9 | 18 | N/A |
| 12/31/2024 | 695 | 23 | 19 | 39 | N/A |
| 9/30/2024 | 652 | 21 | 4 | 24 | N/A |
| 6/30/2024 | 612 | 19 | 8 | 29 | N/A |
| 3/31/2024 | 575 | 16 | 5 | 25 | N/A |
| 12/31/2023 | 545 | 13 | 25 | 33 | N/A |
| 9/30/2023 | 524 | 13 | 14 | 24 | N/A |
| 6/30/2023 | 502 | 13 | 9 | 20 | N/A |
| 3/31/2023 | 486 | 7 | 8 | 22 | N/A |
| 12/31/2022 | 473 | 7 | -5 | 9 | N/A |
| 9/30/2022 | 460 | 1 | -5 | 8 | N/A |
| 6/30/2022 | 454 | -3 | -13 | -2 | N/A |
| 3/31/2022 | 448 | 3 | -23 | -15 | N/A |
| 12/31/2021 | 440 | 3 | -25 | -18 | N/A |
| 9/30/2021 | 436 | 9 | -20 | -16 | N/A |
| 6/30/2021 | 422 | 12 | -9 | -5 | N/A |
| 3/31/2021 | 405 | 14 | 36 | 41 | N/A |
| 12/31/2020 | 391 | 16 | 43 | 50 | N/A |
| 9/30/2020 | 372 | 8 | 41 | 50 | N/A |
| 6/30/2020 | 362 | 5 | 40 | 49 | N/A |
| 3/31/2020 | 352 | 4 | N/A | 13 | N/A |
| 12/31/2019 | 339 | 3 | N/A | 10 | N/A |
| 9/30/2019 | 324 | 10 | N/A | 19 | N/A |
| 6/30/2019 | 309 | 13 | N/A | 18 | N/A |
| 3/31/2019 | 296 | 14 | N/A | 19 | N/A |
| 12/31/2018 | 286 | 16 | N/A | 23 | N/A |
| 12/31/2017 | 251 | 10 | N/A | 17 | N/A |
| 12/31/2016 | 217 | 8 | N/A | 16 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: PNTG s prognostiserade vinsttillväxt ( 28.2% per år) är över sparkvoten ( 3.7% ).
Resultat vs marknad: PNTG s intäkter ( 28.2% per år) förväntas växa snabbare än marknaden för US ( 17.1% per år).
Höga tillväxtresultat: PNTG s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: PNTG s intäkter ( 7.7% per år) förväntas växa långsammare än marknaden för US ( 13% per år).
Hög tillväxtintäkter: PNTG s intäkter ( 7.7% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om PNTG s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/09 14:20 |
| Aktiekurs vid dagens slut | 2026/08/07 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
The Pennant Group, Inc. bevakas av 8 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |